Identification of a three-gene expression signature of early recurrence in non-muscle-invasive urothelial cell carcinoma of the bladder

Urologic Oncology: Seminars and Original Investigations

Volumn 30, Issue 6, 2012, Pages 833-840

  Dubosq, Francis ^a   Ploussard, Guillaume ^a   Soliman, Hany ^a,c   Turpin, Elisabeth ^a   Latil, Alain ^b   Desgrandchamps, François ^a   de The, Hugues ^a,c   Mongiat Artus, Pierre ^a,c  

^a SAINT LOUIS HOSPITAL   (France)

^b Parc Scientifique de Luminy   (France)

^c UNIVERSITÉ PARIS DIDEROT   (France)

Author keywords

Gene profiling; Non muscle invasive; Prognostic factor; Urinary bladder; Urothelial cell carcinoma

Indexed keywords

CAVEOLIN 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; STATHMIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CHI SQUARE TEST; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MALE; NON MUSCLE INVASIVE BLADDER CANCER; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION;

AREA UNDER CURVE; CARCINOMA, TRANSITIONAL CELL; CAVEOLIN 2; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PPAR GAMMA; PROPORTIONAL HAZARDS MODELS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; ROC CURVE; STATHMIN; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84870562861     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2011.02.018     Document Type: Article

References (23)

1. Zieger K., Wolf H., Olsen P.R., et al. Long-term follow-up of noninvasive bladder tumors (stage Ta): Recurrence and progression. BJU Int 2000, 85:824-828.
2. Kurth K.H., Denis L., Bouffioux C., et al. Factors affecting recurrence and progression in superficial bladder tumors. Eur J Cancer 1995, 31A:1840-1846.
3. Sylvester R.J., van der Meijden A.P., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006, 49. 466-5.
4. van Rhijn B.W., Burger M., Lotan Y., et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: From epidemiology to treatment strategy. Eur Urol 2009, 56:430-442.
5. Babjuk M., Oosterlinck W., Sylvester R., et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008, 54:303-314. European Association of Urology (EAU).
6. Mitra A.P., Pagliarulo V., Yang D., et al. Generation of a concise gene panel for outcome prediction in urinary bladder cancer. J Clin Oncol 2009, 27:3929-3937.
7. Birkhahn M., Mitra A.P., Williams A.J., et al. Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profiles. Eur Urol 2010, 57:12-20.
8. Wang R., Morris D.S., Tomlins S.A., et al. Development of a multiplex quantitative PCR signature to predict progression in non-muscle-invasive bladder cancer. Cancer Res 2009, 69:3810-3818.
9. Catto J.W., Abbod M.F., Wild P.J., et al. The application of artificial intelligence to microarray data: Identification of a novel gene signature to identify bladder cancer progression. Eur Urol 2010, 57:398-406.
10. Dyrskjøt L, Zieger K, Real FX, et al. Gene expression signatures predict outcome in non-muscle invasive bladder carcinoma: A multicenter validation study. Clin Cancer Res 200;13:3545-51.
11. Mitra A.P., Datar R.H., Cote R.J. Molecular pathways in invasive bladder cancer: New insights into mechanisms, progression, and target identification. J Clin Oncol 2006, 24:5552-5564.
12. Mitra A.P., Cote R.J. Molecular pathogenesis and diagnostics of bladder cancer. Annu Rev Pathol 2009, 4:251-285.
13. Shariat S.F., Zippe C., Lüdecke G., et al. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1, or CIS transitional cell carcinoma of the bladder. J Urol 2005, 173:1518-1525.
14. Schmitz-Drager B.J., Goebell P.J., Ebert T., et al. p53 Immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists?. Eur Urol 2000, 38:691-700.
15. McShane L.M., Aamodt R., Cordon-Cardo C., et al. Reproducibility of p53 immunohistochemistry in bladder tumors. National Cancer Institute, Bladder Tumor Marker Network. Clin Cancer Res 2000, 6:1854-1864.
16. Dyrskjot L., Thykjaer T., Kruhoffer M., et al. Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet 2003, 33:90-96.
17. Bustin S.A. Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): Trends and problems. J Mol Endocrinol 2002, 29:23-39.
18. Yoshimura R., Matsuyama M., Segawa Y., et al. Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer 2003, 104:597-602.
19. Nakashiro K.I., Hayashi Y., Kita A., et al. Role of peroxisome proliferator-activated receptor gamma and its ligands in non-neoplastic and neoplastic human urothelial cells. Am J Pathol 2001, 159:591-597.
20. Engelman J.A., Zhang X.L., Lisanti M.P. Genes encoding human caveolin-1 and -2 are co-localized to the D7S522 locus (7q31.1), a known fragile site (FRA7G) that is frequently deleted in human cancers. FEBS Lett 1998, 436:403-410.
21. Fong A., Garcia E., Gwynn L., et al. Expression of caveolin-1 and caveolin-2 in urothelial carcinoma of the urinary bladder correlates with tumor grade and squamous differentiation. Am J Clin Pathol 2003, 120:93-100.
22. Rajjayabun P.H., Garg S., Durkan G.C., et al. Caveolin-1 expression is associated with high-grade bladder cancer. Urology 2001, 58:811-814.
23. Mistry S.J., Atweh G.F. Role of stathmin in the regulation of the mitotic spindle: Potential applications in cancer therapy. Mt Sinai J Med 2002, 69:299-304.